June 17, 2024

Pharmaceutical Contract Sales Outsourcing (CSO) Market Size Analysis 2023 To 2032

The global pharmaceutical contract sales outsourcing market size accounted for US$ 9.23 Bn in 2022 and is projected to reach around USD 21.24 Bn by 2032, growing at a CAGR of 8.69% from 2023 to 2032.

Pharmaceutical Contract Sales Outsourcing [CSO] Market Size 2023 To 2032

Report Summary

The global pharmaceutical contract sales outsourcing market report provides a Point-by-Point and In-Depth analysis of global market size, regional and country-level market size, market share, segmentation market growth, competitive landscape, sales analysis, opportunities analysis, strategic market growth analysis, the impact of domestic and global market key players, value chain optimization, trade regulations, recent developments, product launches, area marketplace expanding, and technological innovations.

The study offers a comprehensive analysis on diverse features, including production capacities, demand, product developments, revenue generation, and sales in the pharmaceutical contract sales outsourcing market across the globe.

A comprehensive estimate on the pharmaceutical contract sales outsourcing market has been provided through an optimistic scenario as well as a conservative scenario, taking into account the sales of pharmaceutical contract sales outsourcing during the forecast period. Price point comparison by region with global average price is also considered in the study.

Download Access to a Free Copy of Our Latest Sample Report@ https://www.precedenceresearch.com/sample/2766

 Pharmaceutical Contract Sales Outsourcing (CSO) Market Report Scope 

Report CoverageDetails
Market Size in 2023USD 10.03 Billion
Market Size by 2032USD 21.24 Billion
Growth Rate from 2023 to 2032CAGR of 8.69%
Largest MarketNorth America
Base Year2022
Forecast Period2023 to 2032
Segments CoveredBy Service and By Therapeutic Area
Regions CoveredNorth America, Europe, Asia-Pacific, Latin America and Middle East & Africa

Key Highlights:

Reports Coverage: It incorporates key market sections, key makers secured, the extent of items offered in the years considered, worldwide containerized pharmaceutical contract sales outsourcing market and study goals. Moreover, it contacts the division study gave in the report based on the sort of item and applications.

Market Outline: This area stresses the key investigations, market development rate, serious scene, market drivers, patterns, and issues notwithstanding the naturally visible pointers.

Market Production by Region: The report conveys information identified with import and fare, income, creation, and key players of every single local market contemplated are canvassed right now.

Also Read: Protein Engineering Market Size To Cross USD 15.25 Bn By 2032

 Pharmaceutical Contract Sales Outsourcing (CSO) Market Players

The report includes the profiles of key pharmaceutical contract sales outsourcing market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information, key development in past five years.

Major companies operating in this area

  • IQVIA Inc.
  • Syneos Health Inc.
  • Parexel International Corporation
  • Pharmaceutical Product Development (PPD) LLC
  • inVentiv Health Inc. (part of Syneos Health)
  • ICON plc
  • Publicis Touchpoint Solutions, Inc.
  • PRA Health Sciences, Inc.
  • The Medical Affairs Company (TMAC)
  • Ashfield Healthcare Communications Group (part of UDG Healthcare plc)

Market Segmentation

By Service

  • Personal Promotion
  • Non-personal Promotion
  • Others

By Therapeutic Area

  • Cardiovascular Disorders
  • Oncology
  • Metabolic Disorders
  • Neurology
  • Orthopedic Diseases
  • Infectious Diseases
  • Others

Regional Segmentation

  • North America (U.S., Canada, Mexico)
  • Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
  • Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)
  • Latin America (Brazil and Rest of Latin America)
  • Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)

Research Methodology

Secondary Research

It involves company databases such as Hoover’s: This assists us to recognize financial information, the structure of the market participants and industry’s competitive landscape.

The secondary research sources referred in the process are as follows:

  • Governmental bodies, and organizations creating economic policies
  • National and international social welfare institutions
  • Company websites, financial reports and SEC filings, broker and investor reports
  • Related patent and regulatory databases
  • Statistical databases and market reports
  • Corporate Presentations, news, press release, and specification sheet of Manufacturers

Primary Research

Primary research includes face-to-face interviews, online surveys, and telephonic interviews.

  • Means of primary research: Email interactions, telephonic discussions and Questionnaire-based research etc.
  • In order to validate our research findings and analysis, we conduct primary interviews of key industry participants. Insights from primary respondents help in validating the secondary research findings. It also develops Research Team’s expertise and market understanding.

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Pharmaceutical Contract Sales Outsourcing (CSO) Market 

5.1. COVID-19 Landscape: Pharmaceutical Contract Sales Outsourcing (CSO) Industry Impact

5.2. COVID 19 – Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Pharmaceutical Contract Sales Outsourcing (CSO) Market, By Service

8.1. Pharmaceutical Contract Sales Outsourcing (CSO) Market, by Service, 2023-2032

8.1.1. Personal Promotion

8.1.1.1. Market Revenue and Forecast (2020-2032)

8.1.2. Non-personal Promotion

8.1.2.1. Market Revenue and Forecast (2020-2032)

8.1.3. Others

8.1.3.1. Market Revenue and Forecast (2020-2032)

Chapter 9. Global Pharmaceutical Contract Sales Outsourcing (CSO) Market, By Therapeutic Area

9.1. Pharmaceutical Contract Sales Outsourcing (CSO) Market, by Therapeutic Area, 2023-2032

9.1.1. Cardiovascular Disorders

9.1.1.1. Market Revenue and Forecast (2020-2032)

9.1.2. Oncology

9.1.2.1. Market Revenue and Forecast (2020-2032)

9.1.3. Metabolic Disorders

9.1.3.1. Market Revenue and Forecast (2020-2032)

9.1.4. Neurology

9.1.4.1. Market Revenue and Forecast (2020-2032)

9.1.5. Orthopedic Diseases

9.1.5.1. Market Revenue and Forecast (2020-2032)

9.1.6. Infectious Diseases

9.1.6.1. Market Revenue and Forecast (2020-2032)

9.1.7. Others

9.1.7.1. Market Revenue and Forecast (2020-2032)

Chapter 10. Global Pharmaceutical Contract Sales Outsourcing (CSO) Market, Regional Estimates and Trend Forecast

10.1. North America

10.1.1. Market Revenue and Forecast, by Service (2020-2032)

10.1.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

10.1.3. U.S.

10.1.3.1. Market Revenue and Forecast, by Service (2020-2032)

10.1.3.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

10.1.4. Rest of North America

10.1.4.1. Market Revenue and Forecast, by Service (2020-2032)

10.1.4.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

10.2. Europe

10.2.1. Market Revenue and Forecast, by Service (2020-2032)

10.2.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

10.2.3. UK

10.2.3.1. Market Revenue and Forecast, by Service (2020-2032)

10.2.3.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

10.2.4. Germany

10.2.4.1. Market Revenue and Forecast, by Service (2020-2032)

10.2.4.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

10.2.5. France

10.2.5.1. Market Revenue and Forecast, by Service (2020-2032)

10.2.5.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

10.2.6. Rest of Europe

10.2.6.1. Market Revenue and Forecast, by Service (2020-2032)

10.2.6.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

10.3. APAC

10.3.1. Market Revenue and Forecast, by Service (2020-2032)

10.3.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

10.3.3. India

10.3.3.1. Market Revenue and Forecast, by Service (2020-2032)

10.3.3.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

10.3.4. China

10.3.4.1. Market Revenue and Forecast, by Service (2020-2032)

10.3.4.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

10.3.5. Japan

10.3.5.1. Market Revenue and Forecast, by Service (2020-2032)

10.3.5.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

10.3.6. Rest of APAC

10.3.6.1. Market Revenue and Forecast, by Service (2020-2032)

10.3.6.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

10.4. MEA

10.4.1. Market Revenue and Forecast, by Service (2020-2032)

10.4.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

10.4.3. GCC

10.4.3.1. Market Revenue and Forecast, by Service (2020-2032)

10.4.3.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

10.4.4. North Africa

10.4.4.1. Market Revenue and Forecast, by Service (2020-2032)

10.4.4.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

10.4.5. South Africa

10.4.5.1. Market Revenue and Forecast, by Service (2020-2032)

10.4.5.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

10.4.6. Rest of MEA

10.4.6.1. Market Revenue and Forecast, by Service (2020-2032)

10.4.6.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

10.5. Latin America

10.5.1. Market Revenue and Forecast, by Service (2020-2032)

10.5.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

10.5.3. Brazil

10.5.3.1. Market Revenue and Forecast, by Service (2020-2032)

10.5.3.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

10.5.4. Rest of LATAM

10.5.4.1. Market Revenue and Forecast, by Service (2020-2032)

10.5.4.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

Chapter 11. Company Profiles

11.1. IQVIA Inc.

11.1.1. Company Overview

11.1.2. Product Offerings

11.1.3. Financial Performance

11.1.4. Recent Initiatives

11.2. Syneos Health Inc.

11.2.1. Company Overview

11.2.2. Product Offerings

11.2.3. Financial Performance

11.2.4. Recent Initiatives

11.3. Parexel International Corporation

11.3.1. Company Overview

11.3.2. Product Offerings

11.3.3. Financial Performance

11.3.4. Recent Initiatives

11.4. Pharmaceutical Product Development (PPD) LLC

11.4.1. Company Overview

11.4.2. Product Offerings

11.4.3. Financial Performance

11.4.4. Recent Initiatives

11.5. inVentiv Health Inc. (part of Syneos Health)

11.5.1. Company Overview

11.5.2. Product Offerings

11.5.3. Financial Performance

11.5.4. Recent Initiatives

11.6. ICON plc

11.6.1. Company Overview

11.6.2. Product Offerings

11.6.3. Financial Performance

11.6.4. Recent Initiatives

11.7. Publicis Touchpoint Solutions, Inc.

11.7.1. Company Overview

11.7.2. Product Offerings

11.7.3. Financial Performance

11.7.4. Recent Initiatives

11.8. PRA Health Sciences, Inc.

11.8.1. Company Overview

11.8.2. Product Offerings

11.8.3. Financial Performance

11.8.4. Recent Initiatives

11.9. The Medical Affairs Company (TMAC)

11.9.1. Company Overview

11.9.2. Product Offerings

11.9.3. Financial Performance

11.9.4. Recent Initiatives

11.10. Ashfield Healthcare Communications Group (part of UDG Healthcare plc)

11.10.1. Company Overview

11.10.2. Product Offerings

11.10.3. Financial Performance

11.10.4. Recent Initiatives

Chapter 12. Research Methodology

12.1. Primary Research

12.2. Secondary Research

12.3. Assumptions

Chapter 13. Appendix

13.1. About Us

13.2. Glossary of Terms

Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Emailsales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Blog: https://www.pharma-geek.com